Yttrium-90 (90Y) microsphere therapy is being utilized as a treatment option for patients with primary and metastatic liver cancer due to its ability to target tumors within the liver. The success of this treatment is dependent on many factors, including the extent and type of disease and the nature of prior treatments received. Metabolic activity, as determined by PET imaging, may correlate with the number of viable cancer cells and reflect changes in viable cancer cell volume. However, contouring of PET images by hand is labor intensive and introduces an element of irreproducibility into the determination of functional target/tumor volume (FTV). A computer-assisted method to aid in the automatic contouring of FTV has the potential to subs...
A 54-year-old woman with metastatic colorectal carcinoma underwent liver radioembolization with (90)...
Abstract Background The aim of this study was to investigate the relationship between absorbed dose ...
PURPOSE: The purpose of this phase II study was to determine the safety and efficacy of TheraSphere ...
To compare the value of pretreatment functional and morphological imaging parameters for predicting ...
Selective internal radiotherapy (SIRT) using Yttrium-90 labeled resin microspheres is increasingly u...
90Y-radioembolization using glass or resin microspheres is increasingly used for the treatment of he...
Liver cancer ranks the third most common cause of cancer related mortality worldwide. Radiomicrosphe...
PurposeThe purpose of our study is to determine if there is a relationship between dose deposition m...
PurposeThe primary purpose of this study was to demonstrate intraobserver/interobserver reproducibil...
Purpose: To Evaluate the correlation between tumor dosimetric parameters with objective tumor respon...
Radioembolization of liver tumors using yttrium-90 (Y-90) labeled microspheres is a proven method of...
In transarterial radioembolization (TARE) of hepatocellular carcinoma (HCC) with Yttrium-90 (Y-90) m...
90Y-microsphere therapy has been widely accepted as a treatment option for both primary and metastat...
Radioembolization (RE) with glass microspheres (MS) loaded with Yttrium-90 (90Y) has been used to tr...
International audienceUNLABELLED: Several treatment strategies are used for selective internal radia...
A 54-year-old woman with metastatic colorectal carcinoma underwent liver radioembolization with (90)...
Abstract Background The aim of this study was to investigate the relationship between absorbed dose ...
PURPOSE: The purpose of this phase II study was to determine the safety and efficacy of TheraSphere ...
To compare the value of pretreatment functional and morphological imaging parameters for predicting ...
Selective internal radiotherapy (SIRT) using Yttrium-90 labeled resin microspheres is increasingly u...
90Y-radioembolization using glass or resin microspheres is increasingly used for the treatment of he...
Liver cancer ranks the third most common cause of cancer related mortality worldwide. Radiomicrosphe...
PurposeThe purpose of our study is to determine if there is a relationship between dose deposition m...
PurposeThe primary purpose of this study was to demonstrate intraobserver/interobserver reproducibil...
Purpose: To Evaluate the correlation between tumor dosimetric parameters with objective tumor respon...
Radioembolization of liver tumors using yttrium-90 (Y-90) labeled microspheres is a proven method of...
In transarterial radioembolization (TARE) of hepatocellular carcinoma (HCC) with Yttrium-90 (Y-90) m...
90Y-microsphere therapy has been widely accepted as a treatment option for both primary and metastat...
Radioembolization (RE) with glass microspheres (MS) loaded with Yttrium-90 (90Y) has been used to tr...
International audienceUNLABELLED: Several treatment strategies are used for selective internal radia...
A 54-year-old woman with metastatic colorectal carcinoma underwent liver radioembolization with (90)...
Abstract Background The aim of this study was to investigate the relationship between absorbed dose ...
PURPOSE: The purpose of this phase II study was to determine the safety and efficacy of TheraSphere ...